Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Liu, Huei Chun ^a,b   Ting, Chen Hung ^a   Wen, Hsin Lan ^a   Tsai, Li Kai ^c   Hsieh Li, Hsiu Mei ^d   Li, Hung ^a   Lin Chao, Sue ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

Combined treatment; L ascorbic acid; SMA; Vanadate

Indexed keywords

ASCORBIC ACID; PROTEIN BAX; VANADATE SODIUM;

ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; DISEASE COURSE; DRUG EFFICACY; FIBROBLAST; IN VITRO STUDY; MOTONEURON; MOTOR PERFORMANCE; MUSCLE ATROPHY; MUSCLE WEAKNESS; SPINAL MUSCULAR ATROPHY; SURVIVAL RATE;

ADULT; ANIMALS; ASCORBIC ACID; CELLS, CULTURED; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOTOR SKILLS; MUSCLE WEAKNESS; MUSCULAR ATROPHY; MUSCULAR ATROPHY, SPINAL; VANADATES;

EID: 84873579368     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-38     Document Type: Article

References (77)

1. Sumner CJ. Therapeutics development for spinal muscular atrophy. NeuroRx 2006, 3:235-245. 10.1016/j.nurx.2006.01.010, 16554261.
2. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008, 371:2120-2133. 10.1016/S0140-6736(08)60921-6, 18572081.
3. Briese M, Esmaeili B, Sattelle DB. Is spinal muscular atrophy the result of defects in motor neuron processes?. BioEssays 2005, 27:946-957. 10.1002/bies.20283, 16108074.
4. Hirtz D, Iannaccone S, Heemskerk J, Gwinn-Hardy K, Moxley R, Rowland LP. Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 2005, 65:1352-1357. 10.1212/01.wnl.0000183282.10946.c7, 16275820.
5. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Pasiler D, Frézal J, Cohen D, Weissenbach J, Munnich A, Melki J. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165. 10.1016/0092-8674(95)90460-3, 7813012.
6. Rodrigues NR, Owen N, Talbot K, Ignatius J, Dubowitz V, Davies KE. Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy. Hum Mol Genet 1995, 4:631-634. 10.1093/hmg/4.4.631, 7633412.
7. Parsons DW, McAndrew PE, Iannaccone ST, Mendell JR, Burghes AH, Prior TW. Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet 1998, 63:1712-1723. 10.1086/302160, 1377643, 9837824.
8. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet 2002, 111:477-500. 10.1007/s00439-002-0828-x, 12436240.
9. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999, 96:6307-6311. 10.1073/pnas.96.11.6307, 26877, 10339583.
10. Lorson CL, Androphy EJ. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 2000, 9:259-265. 10.1093/hmg/9.2.259, 10607836.
11. Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet 1997, 61:40-50. 10.1086/513886, 1715870, 9245983.
12. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, Jablonka S, Schrank B, Rossoll W, Prior TW, Morris GE, Burghes AH. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000, 9:333-339. 10.1093/hmg/9.3.333, 10655541.
13. Gavrilov DK, Shi X, Das K, Gilliam TC, Wang CH. Differential SMN2 expression associated with SMA severity. Nat Genet 1998, 20:230-231. 10.1038/3030, 9806538.
14. Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, Coulson SE, Androphy EJ, Prior TW, Burghes AH. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 1997, 6:1205-1214. 10.1093/hmg/6.8.1205, 9259265.
15. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, Dreyfuss G, Melki J. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997, 16:265-269. 10.1038/ng0797-265, 9207792.
16. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H. A mouse model for spinal muscular atrophy. Nat Genet 2000, 24:66-70. 10.1038/71709, 10615130.
17. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001, 98:9808-9813. 10.1073/pnas.171105098, 55534, 11504946.
18. Tsai LK, Tsai MS, Ting CH, Li H. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med (Berl) 2008, 86:1243-1254.
19. Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, Cizman Z, Di Prospero NA, Pellizzoni L, Fischbeck KH, Sumner CJ. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007, 117:659-671. 10.1172/JCI29562, 1797603, 17318264.
20. Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet 2010, 19:1492-1506. 10.1093/hmg/ddq023, 20097677.
21. Garbes L, Riessland M, Holker I, Heller R, Hauke J, Trankle C, Coras R, Blumcke I, Hahnen E, Wirth B. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 2009, 18:3645-3658. 10.1093/hmg/ddp313, 19584083.
22. Farooq F, Molina FA, Hadwen J, Mackenzie D, Witherspoon L, Osmond M, Holcik M, Mackenzie A. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J Clin Invest 2011, 121:3042-3050. 10.1172/JCI46276, 3148738, 21785216.
23. Zhang ML, Lorson CL, Androphy EJ, Zhou J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 2001, 8:1532-1538. 10.1038/sj.gt.3301550, 11704813.
24. Angelozzi C, Borgo F, Tiziano FD, Martella A, Neri G, Brahe C. Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 2008, 45:29-31.
25. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008, 82:834-848. 10.1016/j.ajhg.2008.01.014, 2427210, 18371932.
26. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010, 24:1634-1644. 10.1101/gad.1941310, 2912561, 20624852.
27. Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, Hua Y, Rigo F, Matson J, Hung G, Kaye EM, Shihabuddin LS, Krainer AR, Bennett CF, Cheng SH. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011, 3:72ra18. 10.1126/scitranslmed.3001777, 3140425, 21368223.
28. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011, 478:123-126. 10.1038/nature10485, 3191865, 21979052.
29. Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, Krosschell KJ, D'Anjou G, Bromberg MB, Schroth MK, Chan GM, Elsheikh B, Simard LR. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009, 4:e5268. 10.1371/journal.pone.0005268, 2680034, 19440247.
30. Oskoui M, Kaufmann P. Spinal muscular atrophy. Neurotherapeutics 2008, 5:499-506. 10.1016/j.nurt.2008.08.007, 19019300.
31. Ting CH, Lin CW, Wen SL, Hsieh-Li HM, Li H. Stat5 constitutive activation rescues defects in spinal muscular atrophy. Hum Mol Genet 2007, 16:499-514. 10.1093/hmg/ddl482, 17220171.
32. Meyerovitch J, Farfel Z, Sack J, Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J Biol Chem 1987, 262:6658-6662.
33. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995, 95:2501-2509. 10.1172/JCI117951, 295932, 7769096.
34. Ding W, Hasegawa T, Hosaka H, Peng D, Takahashi K, Seko Y. Effect of long-term treatment with vanadate in drinking water on KK mice with genetic non-insulin-dependent diabetes mellitus. Biol Trace Elem Res 2001, 80:159-174. 10.1385/BTER:80:2:159, 11437181.
35. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C. Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem 2009, 103:554-558. 10.1016/j.jinorgbio.2008.12.003, 19162329.
36. Paternain JL, Domingo JL, Gomez M, Ortega A, Corbella J. Developmental toxicity of vanadium in mice after oral administration. J Appl Toxicol 1990, 10:181-186. 10.1002/jat.2550100307, 2380479.
37. Villani P, Cordelli E, Leopardi P, Siniscalchi E, Veschetti E, Fresegna AM, Crebelli R. Evaluation of genotoxicity of oral exposure to tetravalent vanadium in vivo. Toxicol Lett 2007, 170:11-18. 10.1016/j.toxlet.2006.07.343, 17374461.
38. Sanchez D, Ortega A, Domingo JL, Corbella J. Developmental toxicity evaluation of orthovanadate in the mouse. Biol Trace Elem Res 1991, 30:219-226. 10.1007/BF02991416, 1720642.
39. Domingo JL, Llobet JM, Corbella J. Protection of mice against the lethal effects of sodium metavanadate: a quantitative comparison of a number of chelating agents. Toxicol Lett 1985, 26:95-99. 10.1016/0378-4274(85)90151-1, 3875913.
40. Domingo JL, Llobet JM, Tomas JM, Corbella J. Influence of chelating agents on the toxicity, distribution and excretion of vanadium in mice. J Appl Toxicol 1986, 6:337-341. 10.1002/jat.2550060507, 3772010.
41. Sanchez DJ, Colomina MT, Domingo JL, Corbella J. Prevention by sodium 4,5-dihydroxybenzene-1,3-disulfonate (Tiron) of vanadium-induced behavioral toxicity in rats. Biol Trace Elem Res 1999, 69:249-259. 10.1007/BF02783877, 10468162.
42. Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL. Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Mol Cell Biochem 1995, 153:233-240. 10.1007/BF01075942, 8927043.
43. Baran EJ. Vanadium detoxification: chemical and biochemical aspects. Chem Biodivers 2008, 5:1475-1484. 10.1002/cbdv.200890136, 18729109.
44. Baran EJ. Oxovanadium(IV) and oxovanadium(V) complexes relevant to biological systems. J Inorg Biochem 2000, 80:1-10. 10.1016/S0162-0134(00)00032-5, 10885456.
45. Wilkins PC, Johnson MD, Holder AA, Crans DC. Reduction of vanadium(V) by L-ascorbic acid at low and neutral pH: kinetic, mechanistic, and spectroscopic characterization. Inorg Chem 2006, 45:1471-1479. 10.1021/ic050749g, 16471958.
46. Tsai LK, Tsai MS, Lin TB, Hwu WL, Li H. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis 2006, 24:286-295. 10.1016/j.nbd.2006.07.004, 16952456.
47. Pollard JW, Walker JM. Basic Cell Culture Protocols 1997, Totowa, NJ: Humana Press Inc..
48. Gogliotti RG, Hammond SM, Lutz C, Didonato CJ. Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochem Biophys Res Commun 2010, 391:517-522. 10.1016/j.bbrc.2009.11.090, 2814331, 19961830.
49. Butchbach ME, Edwards JD, Schussler KR, Burghes AH. A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy. J Neurosci Methods 2007, 161:285-290. 10.1016/j.jneumeth.2006.11.002, 2699996, 17161463.
50. Butchbach ME, Edwards JD, Burghes AH. Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol Dis 2007, 27:207-219. 10.1016/j.nbd.2007.04.009, 2700002, 17561409.
51. El-Khodor BF, Edgar N, Chen A, Winberg ML, Joyce C, Brunner D, Suarez-Farinas M, Heyes MP. Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp Neurol 2008, 212:29-43. 10.1016/j.expneurol.2008.02.025, 18455159.
52. Furuse T, Wada Y, Hattori K, Yamada I, Kushida T, Shibukawa Y, Masuya H, Kaneda H, Miura I, Seno N, Kanda T, Hirose R, Toki S, Nakanishi K, Kobayashi K, Sezutsu H, Gondo Y, Noda T, Yuasa S, Wakana S. Phenotypic characterization of a new Grin1 mutant mouse generated by ENU mutagenesis. Eur J Neurosci 2010, 31:1281-1291. 10.1111/j.1460-9568.2010.07164.x, 20345915.
53. Keshet GI, Tolwani RJ, Trejo A, Kraft P, Doyonnas R, Clayberger C, Weimann JM, Blau HM. Increased host neuronal survival and motor function in BMT Parkinsonian mice: involvement of immunosuppression. J Comp Neurol 2007, 504:690-701. 10.1002/cne.21483, 17722033.
54. Ray RS, Ghosh B, Rana A, Chatterjee M. Suppression of cell proliferation, induction of apoptosis and cell cycle arrest: chemopreventive activity of vanadium in vivo and in vitro. Int J Cancer 2007, 120:13-23. 10.1002/ijc.22277, 17058199.
55. Cui W, Cui H, Peng X, Fang J, Zuo Z, Liu X, Wu B. Dietary vanadium induces lymphocyte apoptosis in the bursa of Fabricius of broilers. Biol Trace Elem Res 2012, 146:59-67. 10.1007/s12011-011-9215-6, 21960355.
56. Liu Q, Fischer U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 1997, 90:1013-1021. 10.1016/S0092-8674(00)80367-0, 9323129.
57. Patrizi AL, Tiziano F, Zappata S, Donati MA, Neri G, Brahe C. SMN protein analysis in fibroblast, amniocyte and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis. Eur J Hum Genet 1999, 7:301-309. 10.1038/sj.ejhg.5200286, 10234506.
58. Tsai LK, Tsai MS, Ting CH, Wang SH, Li H. Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy. Neurobiol Dis 2008, 31:361-367. 10.1016/j.nbd.2008.05.014, 18590823.
59. Lutz CM, Kariya S, Patruni S, Osborne MA, Liu D, Henderson CE, Li DK, Pellizzoni L, Rojas J, Valenzuela DM, Murphy AJ, Winberg ML, Monani UR. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest 2011, 121:3029-3041. 10.1172/JCI57291, 3148744, 21785219.
60. Butchbach ME, Singh J, Thorsteinsdottir M, Saieva L, Slominski E, Thurmond J, Andresson T, Zhang J, Edwards JD, Simard LR, Pellizzoni L, Jarecki J, Burghes AH, Gurney ME. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 2010, 19:454-467. 10.1093/hmg/ddp510, 2798721, 19897588.
61. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH, Kaspar BK. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010, 28:271-274. 10.1038/nbt.1610, 2889698, 20190738.
62. Le TT, McGovern VL, Alwine IE, Wang X, Massoni-Laporte A, Rich MM, Burghes AH. Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet 2011, 20:3578-3591. 10.1093/hmg/ddr275, 3159555, 21672919.
63. Rudnik-Schoneborn S, Vogelgesang S, Armbrust S, Graul-Neumann L, Fusch C, Zerres K. Digital necroses and vascular thrombosis in severe spinal muscular atrophy. Muscle Nerve 2010, 42:144-147. 10.1002/mus.21654, 20583119.
64. Araujo Ade Q, Araujo M, Swoboda KJ. Vascular perfusion abnormalities in infants with spinal muscular atrophy. J Pediatr 2009, 155:292-294. 10.1016/j.jpeds.2009.01.071, 3250227, 19619755.
65. Tsai MS, Chiu YT, Wang SH, Hsieh-Li HM, Lian WC, Li H. Abolishing Bax-dependent apoptosis shows beneficial effects on spinal muscular atrophy model mice. Mol Ther 2006, 13:1149-1155. 10.1016/j.ymthe.2006.02.008, 16564230.
66. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O'Riordan CR, Klinger KW, Shihabuddin LS, Cheng SH. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010, 120:1253-1264. 10.1172/JCI41615, 2846065, 20234094.
67. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006, 67:500-501. 10.1212/01.wnl.0000231139.26253.d0, 16775228.
68. Tsai LK, Yang CC, Hwu WL, Li H. Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol 2007, 14:e8-9.
69. Kinali M, Mercuri E, Main M, De Biasia F, Karatza A, Higgins R, Banks LM, Manzur AY, Muntoni F. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002, 59:609-610. 10.1212/WNL.59.4.609, 12196659.
70. Barceloux DG. Vanadium. J Toxicol Clin Toxicol 1999, 37:265-278. 10.1081/CLT-100102425, 10382561.
71. International Atomic Energy Agency WHO, Food and Agriculture Organization of the United Nations Trace Elements in Human Nutrition and Health 1996, Geneva, Switzerland: World Health Organization, International Atomic Energy Agency WHO, Food and Agriculture Organization of the United Nations.
72. Deruelle F, Baron B. Vitamin C: is supplementation necessary for optimal health?. J Altern Complement Med 2008, 14:1291-1298. 10.1089/acm.2008.0165, 19032072.
73. Monani UR, Coovert DD, Burghes AH. Animal models of spinal muscular atrophy. Hum Mol Genet 2000, 9:2451-2457. 10.1093/hmg/9.16.2451, 11005801.
74. Deckwerth TL, Elliott JL, Knudson CM, Johnson EM, Snider WD, Korsmeyer SJ. BAX is required for neuronal death after trophic factor deprivation and during development. Neuron 1996, 17:401-411. 10.1016/S0896-6273(00)80173-7, 8816704.
75. Li S, Zhang T, Yang Z, Gou X. Distribution of vanadium in tissues of nonpregnant and pregnant Wistar rats [in Chinese]. Hua Xi Yi Ke Da Xue Xue Bao 1991, 22:196-200.
76. Edel AL, Kopilas M, Clark TA, Aguilar F, Ganguly PK, Heyliger CE, Pierce GN. Short-term bioaccumulation of vanadium when ingested with a tea decoction in streptozotocin-induced diabetic rats. Metabolism 2006, 55:263-270. 10.1016/j.metabol.2005.08.021, 16423636.
77. Clark TA, Heyliger CE, Kopilas M, Edel AL, Junaid A, Aguilar F, Smyth DD, Thliveris JA, Merchant M, Kim HK, Pierce GN. A tea/vanadate decoction delivered orally over 14 months to diabetic rats induces long-term glycemic stability without organ toxicity. Metabolism 2012, 61:742-753. 10.1016/j.metabol.2011.10.007, 22146096.